DUAVIVE (conjugated estrogens and bazedoxifene modified release tablets) Contraindications

Active or past history of confirmed venous thromboembolism (such as deep vein thrombosis or pulmonary embolism) or active thrombophlebitis.
Active or past history of arterial thromboembolic disease (e.g. stroke, myocardial infarction, coronary heart disease).
Patients who are hypersensitive (for example, angioedema, anaphylaxis) to estrogens, bazedoxifene or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
Undiagnosed abnormal genital bleeding.
Known, suspected, or past history of breast cancer.
Known or suspected estrogen-dependent malignant neoplasia (e.g. endometrial cancer).
Liver dysfunction or disease as long as liver functions tests have failed to return to normal.
Endometrial hyperplasia
Known protein C, protein S, or antithrombin deficiency or other known thrombophilic disorders.
Known or suspected pregnancy, women who may become pregnant, and nursing mothers.
Partial or complete loss of vision due to ophthalmic vascular disease.